Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 26, 2005

View Archived Issues

GRN-163L suppresses human hepatoma growth in mice

Anticocaine antibody prevents death in a model of cocaine overdose

Eight-day oseltamivir dosing more effective than five-day against H5N1 influenza virus in mice

Farnesyltransferase inhibitors show promise for treating progeria

Nanobodies may substitute monoclonal antibodies

AVE-7688 reduces renal fibrosis in COL4A3-/- mice

AlphaRx completes development of vancomycin delivered with nanoparticle delivery platform

Alnylam Pharmaceuticals updates product pipeline

Xoma signs manufacture agreement for Cubist's HepeX-B biologic

Kereos raises funds to support clinical evaluation of MRI agents and therapeutics

Vion initiates solid tumor clinical development program with Cloretazine

Beta-2 adrenergic agonist carmoterol interacts positively with budesonide and tiotropium

Survival benefits of MEDI-522 in advanced melanoma patients

Ruboxistaurin improves renal function in patients with type 2 diabetes and nephropathy

Phase II data on rEV-131 in seasonal allergic rhinitis

Vyteris' Actyve transdermal drug delivery technology shows promise in phase I

Genaissance and Otsuka enter genetic markers research alliance

GSK's Zefix approved in Japan for HBV-associated cirrhosis

XTLbio licenses anti-HCV compounds and technology from VivoQuest

New therapeutic agents disclosed for respiratory disorders

Tripep advances alpha-HGA to phase I/II trial for HIV

Recent patents cover novel treatments for neurological disorders

Cipralex receives European approval for generalized anxiety disorder

Triglyceride reducing agents emerge from Esteve R&D

Studies reveal efficacy of Lanreotide Autogel in acromegaly patients

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...